Eli Lilly (LLY) Net Income towards Common Stockholders (2009 - 2026)

Eli Lilly has reported Net Income towards Common Stockholders for 17 years, with the latest figure at $7.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 168.07% year-over-year to $7.4 billion; the trailing twelve-month figure through Mar 2026 stood at $25.3 billion (up 127.59% YoY), and the FY2025 full-year result was $20.6 billion, up 94.9% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $7.4 billion, up from $6.6 billion in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $7.4 billion in Q1 2026, with the low at -$57.4 million in Q3 2023.
• Historically, Net Income towards Common Stockholders has averaged $2.9 billion across 5 years, with a median of $2.2 billion in 2023.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders sank 103.95% — and 2024, when it surged 1790.42%.
• Eli Lilly's Net Income towards Common Stockholders stood at $1.9 billion in 2022, then climbed by 12.98% to $2.2 billion in 2023, then surged by 101.43% to $4.4 billion in 2024, then jumped by 50.52% to $6.6 billion in 2025, then increased by 11.42% to $7.4 billion in 2026.
• The last three Net Income towards Common Stockholders figures came in at $7.4 billion (Q1 2026), $6.6 billion (Q4 2025), and $5.6 billion (Q3 2025), per Business Quant data.